Compare ASRT & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | ANIX |
|---|---|---|
| Founded | 1995 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 135.3M |
| IPO Year | 1997 | 1987 |
| Metric | ASRT | ANIX |
|---|---|---|
| Price | $0.66 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | 356.0K | ★ 448.6K |
| Earning Date | 11-10-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $137,354,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $0.51 | $2.07 |
| 52 Week High | $1.01 | $5.46 |
| Indicator | ASRT | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 31.93 | 37.50 |
| Support Level | $0.64 | $3.23 |
| Resistance Level | $0.75 | $3.42 |
| Average True Range (ATR) | 0.03 | 0.39 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 12.04 | 5.71 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.